ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 609,15
-0,69%
Dow Jones
39 127,80
0,04%
DAX
18 155,24
-0,04%
Brent Oil
84,295
-0,21%
Bitcoin
60 998,84
0,31%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. First Wave BioPharma Inc (FWBI)

  7. First Wave BioPharma Inc (FWBI) Actualités

FWBI

First Wave BioPharma (FWBI)

First Wave BioPharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:FWBI
DateHeureSourceTitreSymboleSociété
24/06/202414h03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FWBIFirst Wave BioPharma Inc
20/06/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FWBIFirst Wave BioPharma Inc
17/06/202423h23Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:FWBIFirst Wave BioPharma Inc
14/06/202423h15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:FWBIFirst Wave BioPharma Inc
11/06/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:FWBIFirst Wave BioPharma Inc
31/05/202423h25Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:FWBIFirst Wave BioPharma Inc
30/05/202423h32Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:FWBIFirst Wave BioPharma Inc
30/05/202423h18Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:FWBIFirst Wave BioPharma Inc
16/05/202413h00GlobeNewswire Inc.First Wave BioPharma Changes Name to Entero TherapeuticsNASDAQ:FWBIFirst Wave BioPharma Inc
14/05/202423h26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FWBIFirst Wave BioPharma Inc
13/05/202422h59Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:FWBIFirst Wave BioPharma Inc
10/05/202413h55GlobeNewswire Inc.First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-MarketNASDAQ:FWBIFirst Wave BioPharma Inc
09/05/202413h00GlobeNewswire Inc.First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness MonthNASDAQ:FWBIFirst Wave BioPharma Inc
24/04/202413h00GlobeNewswire Inc.First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, NutrientsNASDAQ:FWBIFirst Wave BioPharma Inc
17/04/202413h00GlobeNewswire Inc.First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap ShowcaseNASDAQ:FWBIFirst Wave BioPharma Inc
15/04/202413h00GlobeNewswire Inc.First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders ConferenceNASDAQ:FWBIFirst Wave BioPharma Inc
18/03/202412h00GlobeNewswire Inc.First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) ConferenceNASDAQ:FWBIFirst Wave BioPharma Inc
14/03/202411h00GlobeNewswire Inc.First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical PipelineNASDAQ:FWBIFirst Wave BioPharma Inc
05/03/202413h00GlobeNewswire Inc.First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth ConferenceNASDAQ:FWBIFirst Wave BioPharma Inc
04/03/202414h00GlobeNewswire Inc.First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct OfferingNASDAQ:FWBIFirst Wave BioPharma Inc
13/02/202413h00GlobeNewswire Inc.First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024NASDAQ:FWBIFirst Wave BioPharma Inc
23/01/202413h00GlobeNewswire Inc.First Wave BioPharma to Present at the DealFlow MicroCap ConferenceNASDAQ:FWBIFirst Wave BioPharma Inc
17/01/202422h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FWBIFirst Wave BioPharma Inc
17/01/202413h00GlobeNewswire Inc.First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto RicoNASDAQ:FWBIFirst Wave BioPharma Inc
04/01/202412h00GlobeNewswire Inc.First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024NASDAQ:FWBIFirst Wave BioPharma Inc
28/12/202318h21Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:FWBIFirst Wave BioPharma Inc
27/12/202317h55GlobeNewswire Inc.First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds PricedNASDAQ:FWBIFirst Wave BioPharma Inc
27/12/202314h04Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:FWBIFirst Wave BioPharma Inc
27/12/202312h00GlobeNewswire Inc.First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD ProgramNASDAQ:FWBIFirst Wave BioPharma Inc
18/12/202312h00GlobeNewswire Inc.First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical CompanyNASDAQ:FWBIFirst Wave BioPharma Inc
 Showing the most relevant articles for your search:NASDAQ:FWBI

Dernières Valeurs Consultées

BIT
P1Z216
NLBNPIT1Z216 20991231 78...
TG
A30VUK
Credit Institute for Rec...
LSE
QJ22
Morg.st.b.v 26
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés